Posted by Michael Wonder on 12 Nov 2025
Parabilis Medicines receives FDA fast track designation for FOG-001, the first and only direct inhibitor of the β-catenin:TCF interaction for the treatment of desmoid tumours
12 November 2025 - Parabilis Medicines today announced that the US FDA has granted fast track product designation to FOG-001 for the treatment of desmoid tumours, reflecting significant unmet need and the potential of this first-in-class therapy to transform patient care.
FOG-001, Parabilis’s lead investigational Helicon peptide, is the first and only direct inhibitor of the “undruggable” β-catenin:TCF interaction.
